Fra-1 affects chemotherapy sensitivity by inhibiting ferroptosis in gastric cancer cells

Abstract

Aim: Gastric cancer (GC) is one of the common malignant tumors, and most patients with advanced GC often develop chemotherapy resistance, resulting in poor chemotherapy efficacy. Therefore, it is crucial to clarify the specific mechanisms of their chemotherapy resistance.

Methods: In this study, we analyzed the correlation between fos-related antigen-1 (Fra-1) and chemotherapy resistance in GC using bioinformatics, cell counting kit-8 (CCK8), and 5-ethynyl-2’-deoxyuridine (EDU) combined with flow cytometry; furthermore, we used energy metabolomics sequencing, combined with ChIP-qPCR technology, to elucidate the specific role of Fra-1 in chemotherapy resistance of GC cells and its related mechanisms.

Results: We found that high Fra-1 expression was closely related to chemotherapeutic drugs in GC cells, as demonstrated by bioinformatics analysis combined with EDU and CCK8 experiments. Energy metabolomics combined with in vitro cellular experimental analysis revealed that the pentose phosphate pathway (PPP) was activated in GC cells with high Fra-1 expression, along with an increase in the synthesis of metabolites such as nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione (GSH), a decrease in the level of reactive oxygen species (ROS), and the inhibition of their ferroptosis. In addition, ChIP-qPCR experiments confirmed that Fra-1 binds to the promoter of glucose-6-phosphate dehydrogenase (G6PD), a key rate-limiting enzyme of the PPP, and transcriptionally regulates its expression, which in turn activates the PPP and promotes chemotherapy resistance in GC cells.

Conclusion: Our research findings suggest that Fra-1 activates the PPP by upregulating G6PD transcriptional activity and inhibiting its ubiquitination level, inhibiting ferroptosis in GC cells and inducing chemoresistance. This provides an experimental basis for screening potential molecular targets for chemotherapy resistance in GC patients.

Keywords

Gastric cancer / Fra-1 / G6PD / pentose phosphate pathway / ferroptosis / chemotherapy resistance

References

[1] Guan WL,Xu RH.Gastric cancer treatment: recent progress and future perspectives.J Hematol Oncol2023;16:57 PMCID:PMC10225110

[2] Davodabadi F,Sarhadi M.Cancer chemotherapy resistance: mechanisms and recent breakthrough in targeted drug delivery.Eur J Pharmacol2023;958:176013

[3] Wong TL,Lu S.ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer.Nat Commun2023;14:2861 PMCID:PMC10199093

[4] Stockwell BR.Ferroptosis turns 10: emerging mechanisms, physiological functions, and therapeutic applications.Cell2022;185:2401-21 PMCID:PMC9273022

[5] Wang Y,Ren Z.Overcoming cancer chemotherapy resistance by the induction of ferroptosis.Drug Resist Updat2023;66:100916

[6] Jiang X,Conrad M.Ferroptosis: mechanisms, biology and role in disease.Nat Rev Mol Cell Biol2021;22:266-82 PMCID:PMC8142022

[7] Jiang Z,Yan M.TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis.J Clin Invest2021;131:e139434 PMCID:PMC8262501

[8] Qi R,Li K.Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.Drug Resist Updat2023;68:100960

[9] Zhang H,Liu R.CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer.Mol Cancer2020;19:43 PMCID:PMC7045485

[10] Wang Y,Shang W.Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer.Cell Death Differ2022;29:2190-202 PMCID:PMC9613693

[11] He YY,Chen L.The Fra-1: novel role in regulating extensive immune cell states and affecting inflammatory diseases.Front Immunol2022;13:954744 PMCID:PMC9404335

[12] Zeng F,Jin X.FRA-1: a key factor regulating signal transduction of tumor cells and a potential target molecule for tumor therapy.Biomed Pharmacother2022;150:113037

[13] Gao S,Gang J.Inhibition of hepatocellular carcinoma cell proliferation through regulation of the cell cycle, AGE-RAGE, and leptin signaling pathways by a compound formulation comprised of andrographolide, wogonin, and oroxylin A derived from Andrographis Paniculata(Burm.f.) Nees.J Ethnopharmacol2024;329:118001

[14] Gao S,Li D.Oridonin suppresses gastric cancer SGC-7901 cell proliferation by targeting the TNF-alpha/androgen receptor/TGF-beta signalling pathway axis.J Cell Mol Med2023;27:2661-74 PMCID:PMC10494293

[15] He J,Gao L.Fra-1 is upregulated in gastric cancer tissues and affects the PI3K/Akt and p53 signaling pathway in gastric cancer.Int J Oncol2015;47:1725-34

[16] He J,Jin XI.YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells.Oncol Res2023;31:615-30 PMCID:PMC10319584

[17] Harshitha R.Real-time quantitative PCR: a tool for absolute and relative quantification.Biochem Mol Biol Educ2021;49:800-12

[18] Huang F,Xu L.Hedyotis diffusa injection induces ferroptosis via the Bax/Bcl2/VDAC2/3 axis in lung adenocarcinoma.Phytomedicine2022;104:154319

[19] López MJ,Alfaro AL.Characteristics of gastric cancer around the world.Crit Rev Oncol Hematol2023;181:103841

[20] Arai H.Recent developments of systemic chemotherapy for gastric cancer.Cancers2020;12:1100 PMCID:PMC7281322

[21] Rattanasinchai C,Conrad SE.MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells.Oncogenesis2017;6:e345 PMCID:PMC5519193

[22] Hoang VT,La J.Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.J Cell Biochem2021;122:835-50

[23] Luo YP,Krueger J.The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression.Oncogene2010;29:662-73 PMCID:PMC3032566

[24] Henckels E.Fra-1 regulation of matrix metallopeptidase-1 (MMP-1) in metastatic variants of MDA-MB-231 breast cancer cells.F1000Res2013;2:229 PMCID:PMC4193399

[25] Moquet-Torcy G,Piechaczyk M.Transcriptional complexity and roles of Fra-1/AP-1 at the uPA/Plau locus in aggressive breast cancer.Nucleic Acids Res2014;42:11011-24 PMCID:PMC4176185

[26] Casalino L,Matino I.FRA-1 as a regulator of EMT and metastasis in breast cancer.Int J Mol Sci2023;24:8307 PMCID:PMC10179602

[27] Lu D,Tan X.Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy.Cancer Res2012;72:3451-6

[28] Song D,Sinha I.Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.Cancer Lett2021;506:23-34

[29] Liu H,Wang T.Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.Carcinogenesis2015;36:459-68 PMCID:PMC4392608

[30] Yun SI,Yeo SY,Cho YB.Ubiquitin-specific protease 21 promotes colorectal cancer metastasis by acting as a Fra-1 deubiquitinase.Cancers2020;12:207 PMCID:PMC7017141

[31] Wu J,Zhang PY.The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells.Cell Death Dis2016;7:e2384 PMCID:PMC5059884

[32] Patra KC.The pentose phosphate pathway and cancer.Trends Biochem Sci2014;39:347-54 PMCID:PMC4329227

[33] TeSlaa T,Fan J.The pentose phosphate pathway in health and disease.Nat Metab2023;5:1275-89 PMCID:PMC11251397

[34] Lucke-Wold BP,Turner RC,Rosen CL.Endoplasmic reticulum stress modulation as a target for ameliorating effects of blast induced traumatic brain injury.J Neurotrauma2017;34:S62-70 PMCID:PMC5749601

[35] Li M,Guo W.Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.Nat Cancer2020;1:735-47

[36] Jia D,Zhu Z.Novel transketolase inhibitor oroxylin A suppresses the non-oxidative pentose phosphate pathway and hepatocellular carcinoma tumour growth in mice and patient-derived organoids.Clin Transl Med2022;12:e1095 PMCID:PMC9619225

[37] Franceschi S,Morelli M.Sedoheptulose kinase SHPK expression in glioblastoma: emerging role of the nonoxidative pentose phosphate pathway in tumor proliferation.Int J Mol Sci2022;23:5978 PMCID:PMC9180619

[38] Paul S,Kumar S.Tumor glycolysis, an essential sweet tooth of tumor cells.Semin Cancer Biol2022;86:1216-30

[39] Dong S,Cheng Z.ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.J Exp Clin Cancer Res2022;41:15 PMCID:PMC8742403

[40] Sun M,Niu Y.PRMT6 promotes tumorigenicity and cisplatin response of lung cancer through triggering 6PGD/ENO1 mediated cell metabolism.Acta Pharm Sin B2023;13:157-73 PMCID:PMC9939295

[41] Sun M,Wu T.PIKE-A promotes glioblastoma growth by driving PPP flux through increasing G6PD expression mediated by phosphorylation of STAT3.Biochem Pharmacol2021;192:114736

[42] Shan C,Li Z.4-hydroxyphenylpyruvate dioxygenase promotes lung cancer growth via pentose phosphate pathway (PPP) flux mediated by LKB1-AMPK/HDAC10/G6PD axis.Cell Death Dis2019;10:525 PMCID:PMC6614486

[43] Li E,Ashrafian H,Neves AL.The impact of electronic health record interoperability on safety and quality of care in high-income countries: systematic review.J Med Internet Res2022;24:e38144 PMCID:PMC9523524

[44] Yao X,Fang D.Emerging roles of energy metabolism in ferroptosis regulation of tumor cells.Adv Sci2021;8:e2100997 PMCID:PMC8596140